SPRO
SPRO
NASDAQ · Biotechnology

Spero Therapeutics Inc

$1.19
-0.04 (-3.25%)
Financial Highlights (FY 2026)
Revenue
64.59M
Net Income
8.29M
Gross Margin
—
Profit Margin
12.8%
Rev Growth
+7.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 49.6% 49.6%
Operating Margin 9.4% 8.5% -22.5% -21.2%
Profit Margin 12.8% 12.2% -19.0% -18.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 64.59M 59.98M 30.93M 26.54M
Gross Profit — — 15.33M 13.15M
Operating Income 6.10M 5.10M -6,967,592 -5,637,171
Net Income 8.29M 6.93M -5,880,957 -4,950,304
Gross Margin — — 49.6% 49.6%
Operating Margin 9.4% 8.5% -22.5% -21.2%
Profit Margin 12.8% 12.2% -19.0% -18.7%
Rev Growth +7.7% +7.7% +18.4% +23.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 26.75M 29.13M
Total Equity — — 80.40M 90.84M
D/E Ratio — — 0.33 0.32
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 6.10M 5.38M -8,827,347 -7,842,890
Free Cash Flow — — -6,633,459 -6,096,996